Lenacapavir’s $6,000 Price Tag Threatens HIV Access
The FDA approved lenacapavir, an HIV shot with over 99% efficacy, but its $6,000 price tag threatens access. This cost barrier risks excluding vulnerable populations in low-income regions from the tre
Business Insider Mkt — 31 July 2026
Text:
37
0
0
The FDA has cleared lenacapavir, a long‑acting HIV shot that could cut infection risk to almost zero, but the drug’s price threatens to keep it out of
Read Full Story at Business Insider Mkt → Sources
🏥 Health
Ebola kills over 1,700 in eastern Congo outbreak
🏥 Health
One Big Beautiful Bill cut healthcare funds. Now, Republicans have to sell the costs
🏥 Health
Louisiana reports five vibriosis deaths in 2024
🏥 Health
Hunter Biden says Joe Biden's prostate cancer spreads
🏥 Health
Senate confirms Dr. Erica Schwartz as CDC director after year-long vacancy
🏥 Health
Measles outbreak in 2025 costs $5.4 million to contain, study finds
